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IllustratIve case 
a	39-year-old,	otherwise	healthy	woman	
presents	to	your	clinic	with	a	sore	throat,	
nasal	congestion,	and	dry	cough	she’s	had	
since	yesterday.	She	wants	an	antibiotic,	
but	your	evaluation	reveals	an	uncompli-
cated	viral	upper	respiratory	infection—a	
common	cold.	You	would	like	to	provide	
her	with	an	alternative	treatment,	but	you	
are	aware	of	the	lack	of	evidence	for	clear	
benefit	of	zinc	lozenges,	echinacea,	and	
vitamin	c.	Is	there	any	other	medication	
that	might	benefit	this	patient?
Yes. Pelargonium sidoides, a species of 
South African geranium used for centu-
ries in Zulu medicine,2 shows promise as 
an herbal remedy for respiratory infec-
tions. Two randomized trials show that 
extracts of P sidoides improve symptoms 
of acute bronchitis which, like the com-
mon cold, is usually caused by a virus.3–5
There is a plausible biological mecha-
nism of action. In vitro studies show that 
Pelargonium extract induces the inter-
feron system and up-regulates cytokines 
important in protecting host cells from 
viral infection.6
background
z  $17 billion dollar cold
Our patients want more relief from cold 
symptoms and are clearly willing to pay 
for it. Americans spend approximately 
$2.9 billion annually on over-the-coun-
ter (OTC) cold preparations and $1.1 
billion on unnecessary antibiotics.7 The 
term “common cold” refers to a collec-
tion of symptoms, including sore throat, 
rhinorrhea, nasal congestion, cough, 
low-grade fever, and malaise, usually 
self-limited and lasting 10 to 14 days, 
caused by a number of viruses, most 
commonly by a rhinovirus.8 According 
to the 2005 National Ambulatory Med-
ical Care Survey, the common cold is the 
third most common diagnosis in physi-
cians’ offices behind only hypertension 
and well-infant/child visits.9 A 2001 
US telephone survey determined that 
approximately 500 million episodes of 
non-influenza viral infection occur an-
nually, resulting in direct costs of $17 
billion for physician services and medi-
cations and approximately 200 million 
missed days of work.7 
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offer	patients	Pelargonium 
sidoides	(30	drops	3	times	a	
day)	to	reduce	the	severity	
and	duration	of	common	cold	
symptoms	and	to	get	patients	
back	to	work	sooner.1
Strength	of	recommendation	
b: a	single	well-designed	randomized	controlled	trial
lizogub	vG,	riley	DS,	heger	M.	Efficacy	of	a	
Pelargonium sidoides preparation	in	patients	with	
the	common	cold:	a	randomized,	double	blind,	
placebo-controlled	clinical	trial.	Explore (NY) 
2007;	3:573-584.
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PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and findings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
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clInIcal context
z  Evidence proves most 
cold remedies don’t work
Although colds are common and result 
in annoying symptoms and missed work, 
much of the money spent on remedies is 
wasted. A truly effective treatment would 
be valuable to our patients.
Despite brisk sales, evidence for the 
efficacy of various cold remedies is in-
conclusive and contradictory. We found 
6 Cochrane reviews of cold treatments, 
including antitussives, antihistamines, 
decongestants, vitamin C, echinacea, 
and zinc lozenges. With the exception 
of pseudoephedrine for nasal symptoms, 
the evidence that any product improves 
symptoms or decreases the duration of 
the cold is not encouraging.
cough medications. The 2004 Co-
chrane Review of OTC medications for 
cough10 found no consistent evidence that 
any of them work. Codeine was no more 
effective than placebo for reducing cough 
symptoms. Three efficacy studies of dex-
tromethorphan for cough showed either 
no difference or small but possibly clini-
cally insignificant improvement in cough 
over placebo. One study of guaifenesin 
showed benefit over placebo in reducing 
cough frequency; another one showed no 
benefit over placebo.
vitamin c, echinacea. Three Cochrane 
reviews found no conclusive evidence of 
benefit over placebo for either vitamin 
C11 or echinacea12 in treating the common 
cold. 
Zinc. A new panel has been convened 
by the Cochrane group to reassess the ef-
fectiveness of zinc, but a 1999 Cochrane 
review13 found no benefit for zinc over 
placebo.
antihistamines are not effective for re-
lieving cold symptoms.14 
Pseudoephedrine is the only medica-
tion with good-quality evidence for ef-
fectiveness, but only for reducing nasal 
symptoms.15 The authors concluded that 
patients may be encouraged to continue 
pseudoephedrine for up to 5 days if found 
to be effective with the first dose. Nasal 
congestion and discharge, however, are 
only 2 of the many irritating symptoms of 
a cold. 
study summary
z  Duration and severity  
of symptoms are reduced
This was a multicenter, prospective, dou-
ble-blind, placebo-controlled random-
ized trial to evaluate the effectiveness of a 
liquid herbal preparation from the roots 
of Pelargonium sidoides for decreasing 
the duration and severity of symptoms of 
the common cold.
Patient characteristics. Patients were 
recruited from 8 outpatient departments 
in Ukraine between December 2003 and 
May 2004. Two hundred and seven (207) 
patients were eligible. The number of in-
eligible and excluded patients was not 
stated. These 207 patients were random-
ized into 1 of 4 groups: 
• 52 received 30 drops 3 times daily 
vs 51 patients who received placebo
• 52 patients received 60 drops 
3 times daily vs 52 patients who received 
a higher-dose placebo. 
The report gives the outcomes of 
the low-dose arm only. Two-thirds of 
the participants were women; all were 
Caucasian. Patients in the treatment and 
placebo groups were similar in terms of 
recurrent disease, prior use of medication 
for the common cold, smoking, and al-
cohol and caffeine consumption. All had 
a negative Group A beta-hemolytic strep 
test.
Inclusion criteria. Patients included 
men and women 18 to 55 years of age; 
able to provide written informed con-
sent; with 2 major cold symptoms (na-
sal discharge, sore throat) and at least 
1 minor cold symptom (nasal congestion, 
sneezing, scratchy throat, hoarseness, 
cough, headaches, muscle aches, or fever) 
or presence of 1 major cold symptom and 
at least 3 minor cold symptoms; duration 
of symptoms 24 to 48 hours.
exclusion criteria were any acute 
ear, nose, throat and respiratory tract 
disease other than the common cold; 
you can be a  
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positive rapid strep test; 6 or more epi-
sodes of recurrent tonsillitis, sinusitis, or 
otitis within the past 12 months or any 
chronic ear, nose, throat or respiratory 
tract disease; treatment with antibiotics, 
glucocorticoids, or antihistamine drugs 
during the 4 weeks prior to enrollment 
in the trial; treatment with cold medica-
tions that might impair the trial results 
(eg, decongestants, local anesthetics); and 
use of cough or pain relief medications, 
or any other treatment for the common 
cold within 7 days prior to enrollment in 
the trial.
treatment regimen. Patients were 
assigned to take 30 drops of either the 
study herbal preparation or 30 drops of 
placebo 3 times daily, at least 30 minutes 
before or after a meal, from day 1 con-
tinuing to day 10. The investigational 
drug and placebo were supplied by Dr. 
Willmar Schwabe GmbH & Co. (Karls-
ruhe, Germany). The investigational 
medication is a preparation of the roots 
of P sidoides, extraction solution: etha-
nol 11% (1:8-10) (wt/wt). The placebo 
was matched for color, smell, taste, and 
viscosity. Paracetamol (acetaminophen) 
tablets were allowed for all patients for 
fever greater than 39°C.
Primary endpoint. Severity of cold 
symptoms was evaluated using the Cold 
Intensity Score (CIS), a validated scale 
derived from the sum of scores for 10 
cold-related symptoms (nasal drainage, 
sore throat, nasal congestion, sneezing, 
scratchy throat, hoarseness, cough, head-
aches, muscle aches, and fever) on a scale 
of 0 to 4, where 0 = not present and 4 = 
very severe, to a maximum of 40 points. 
At baseline, the mean total CIS was com-
parable in both treatment and placebo 
groups (17.8 ± 4.0 vs 16.9 ± 3.4). From 
baseline to day 5, the mean total CIS de-
creased by 10.4 ± 3.0 in the treatment 
group vs 5.6 ± 4.3 in the placebo group 
(P<.0001). 
secondary endpoints. The number of 
patients achieving clinical cure (defined 
by CIS ≤1) by day 10 was significantly 
higher in the treatment group (78.8% vs 
31.4%, P<.0001). The mean duration of 
days absent from work was significantly 
lower in the treatment group (6.9 ± 1.8 
vs 8.2 ± 2.1, P<.0003), as was number of 
days with less than 100% usual activity 
level (7.1 ± 1.5 vs 8.7 ± 1.3, P<.0001). 
Data for both the primary and second-
ary endpoints were evaluated according 
to an intention-to-treat analysis. Both the 
intervention and placebo sides each had 
4 patients that became ineligible after ini-
tial randomization. No patients were lost 
to follow-up.
safety and tolerability. Patients in the 
low-dose arm experienced 3 nonserious 
adverse events, and 1 experienced mild 
epistaxis. Two additional patients (1 in 
the treatment and 1 in the placebo group) 
experienced moderate to severe tracheitis, 
not attributable to the study medication. 
Tolerability was rated slightly better in 
the treatment than placebo group on day 
5. Forty-nine of 52 patients (94%) in the 
treatment group rated the preparation as 
good or very good tolerability vs 42 of 51 
patients (82%) in the placebo group.
what’s new?
z  A first
This is the first study that demonstrates 
the efficacy and safety of P sidoides in 
the treatment of the common cold. More 
importantly, this degree of improvement 
in cold symptoms is dramatically better 
than other common OTC treatments, 
including vitamin C, echinacea, and zinc 
preparations.
caveats
z  How is this different  
from other cold remedies?
Patients are already spending a lot on 
cold remedies; this study suggests money 
would be better spent on having a ready 
supply of Pelargonium in the medicine 
cabinet, and it appears to be safe. 
Other initially promising comple-
mentary and alternative therapies, such 
as zinc, echinacea, and vitamin C, have 
not been shown to be effective with more 
vigorous evaluation. We recognize that 
To get the  
benefits, treatment 
must start early. 
Patients could be 
advised to buy  
the medication, 
to have on hand
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this is only 1 clinical trial, and the results 
may not be replicated in future trials. 
However, we are impressed by the ef-
fect size—twice the size as that seen for 
placebo, with a reduction in half of total 
cold symptom severity over 5 days and a 
reduction of missed time from work by 
more than a full day on average over pla-
cebo. 
In vitro studies suggest a physiologic 
mechanism that is consistent with the 
study outcomes. 
Similar findings are reported for 
symptom reduction in acute bronchitis. 
Safety
There were no significant adverse events 
in this study, which is consistent with the 
findings of the studies of acute bronchi-
tis.12–14 P sidoides has been widely used 
in Germany since the 1980s, with an an-
nual sale value in 2002 of $55 million or 
4.1 million packages. 
The Uppsala Monitoring Centre, in 
conjunction with the World Health Or-
ganization international pharmacovigi-
lance program, received 34 case reports 
between 2002 and 2006 of allergic re-
actions to ethanolic herbal extract of 
Pelargonium root, 2 of which involved 
life-threatening circulatory collapse re-
quiring emergency medical attention. 
Given the extremely rare occurrence of 
these events we believe the minimal risk 
is acceptable. The others involved rash 
and pruritus. 
Also of note: contact dermatitis to 
Pelargonium houseplants has been report-
ed. As a result, product information will 
be added to product packaging, warning 
of common reactions of gastrointestinal 
complaints (gastric pain, heartburn, nau-
sea, and diarrhea) as well as the potential 
for serious allergic reaction. In addition, 
since some of the active compounds are 
plant coumarins, there is a theoretical 
risk of interaction with warfarin and as-
pirin but no serious bleeding events have 
been reported.16 
It is also recommended that individu-
als with renal or hepatic disease or wom-
en who are pregnant or breastfeeding 
avoid use of this preparation, as safety 
studies have not been performed.
Other study design issues
A few other issues struck us as important 
when assessing the validity of this study. 
For example, 1 of the authors appears to 
be an employee of the pharmaceutical 
company that manufactures the prepara-
tion, raising the conflict of interest issue. 
We were also curious about why the 
results of the high-dose arm were not re-
ported in this manuscript. Could there 
have been a higher rate of adverse events 
in the high-dose arm? Knowing how 
many patients were ineligible or exclud-
ed, and the efficacy or safety in the high-
dose arm would give us more confidence 
in the findings, but we decided that these 
were not necessarily fatal flaws. 
Bottom line
Despite the above caveats, this was a 
well-designed randomized controlled 
trial that suggests that P sidoides is im-
pressively efficacious in decreasing the 
duration and severity of the common 
cold. In the final analysis, we think that 
these findings justify recommending this 
to our patients.
challenges to ImPlementatIon
z 2-day window
The medication was started within 48 
hours of the onset of symptoms. We 
generally see patients seeking treatment 
for the common cold well after the first 
2 days. The efficacy of Pelargonium is 
no doubt less when started later in the 
course of the illness. Colds resolve spon-
taneously, so to get the benefit of this 
treatment, it likely must be started early. 
Our conclusion is that patients could 
be advised to purchase the medication to 
have on hand at home at the start of the 
cold season.
Availability of the drug
P sidoides is available in the US under 
the brand name Umcka Coldcare.
This degree  
of improvement  
in cold symptoms 
is far better  
than other  
OTC treatments
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Pelargonium sidoides for colds
The preparation used in the study is 
marketed in Europe by ISO-Arzneimit-
tel17 under the name Umckaloabo, which 
is a combination of the Zulu words for 
lung symptoms and breast pain.18
Our Internet search on the term “Pel-
argonium sidoides” failed to yield a dis-
tributor of the German preparation used 
in the study that would be available in 
the United States. However, a different 
manufacturer, Nature’s Way, distributes a 
number of similar preparations contain-
ing extract of the root of P sidoides under 
the name Umcka Coldcare. Umcka Cold-
care appears to be readily available for 
purchase, both on-line and through local 
health food stores, for less than $20 per 
4-oz (120-mL) bottle. A different retailer, 
African Red Tea, offers syrup, 1:10 etha-
nolic extract for $29.95 for 100-mL bot-
tle.19 Like the German preparation, these 
formulations are delivered by dropper.  n
Purls methodology
This	study	was	selected	and	evaluated	using	FPIN’s	Priority	Updates	
from	the	research	literature	(PUrl)	Surveillance	System	method-
ology.	The	criteria	and	findings	leading	to	the	selection	of	this	study	
as	a	PUrl	can	be	accessed	at	www.jfponline.com/purls.	
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